The culmination of 15 years of work saw Perrigo introduce the first generic version of Teva’s ProAir in late February. Preliminary results released by the company for its financial first quarter reveal the launch has provided Perrigo with the expected boost in sales.
Just ten days after its financial first quarter closed, Perrigo has released unaudited financial data suggesting that sales for the company’s Rx Prescription Pharmaceuticals generics business passed a quarter of a billion dollars during the period, thanks in part to the launch of the first generic version of Teva’s ProAir (albuterol sulfate) inhalation aerosol.
Perrigo said its first quarter Prescription first quarter net sales, for the three months ended 28 March, “were approximately $260...
Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.
A weak second half in Glenmark’s India business during the firm’s 2025 financial year took the gloss off its earnings somewhat for the year. However, Glenmark is plotting several avenues to return to growth, in both of its core business regions: India and the US.
Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now
Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.
A proposed biosimilar to one of the lesser spoken about monoclonal antibodies for inflammatory conditions, UCB Pharma’s Cimzia, is the latest candidate to join the significant commercial partnership between Alvotech and Advanz Pharma.
Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.
What makes the generics and biosimilars sector unique when it comes to executive talent searches and recruitment? Dan Nathan, founder and managing director of Parsity Group, talks to Generics Bulletin about how the firm operates in the fast-moving global off-patent industry.
